A prevalence of 60% psychiatric comorbidities has been reported
in patients with CHC. On the other side, neuropsychiatric side
effects occur in up to 50% of patients receiving treatment with
PegIFN/RBV, the commonest being depression. Prospective
clinical trials suggest that patients with HCV infection and
psychiatric comorbidities can be safely treated with interferonbased
antiviral regimens by both hepatologists and mental
health professionals as part of a multidisciplinary team (Knott
2006). An expert psychiatric assessment is required before the
decision about the management of HCV infection in this group of
patients. Through close collaboration between hepatologist and
psychiatrist, a significant proportion of patients with CHC and
well controlled psychiatric comorbidity can safely and
effectively receive antiviral treatment.
in patients with CHC. On the other side, neuropsychiatric side
effects occur in up to 50% of patients receiving treatment with
PegIFN/RBV, the commonest being depression. Prospective
clinical trials suggest that patients with HCV infection and
psychiatric comorbidities can be safely treated with interferonbased
antiviral regimens by both hepatologists and mental
health professionals as part of a multidisciplinary team (Knott
2006). An expert psychiatric assessment is required before the
decision about the management of HCV infection in this group of
patients. Through close collaboration between hepatologist and
psychiatrist, a significant proportion of patients with CHC and
well controlled psychiatric comorbidity can safely and
effectively receive antiviral treatment.
No comments:
Post a Comment